Skip to main content
Erschienen in: CNS Drugs 6/2011

01.06.2011 | Review Article

Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics

verfasst von: Dr Jimmi Nielsen, Claus Graff, Jørgen K. Kanters, Egon Toft, David Taylor, Jonathan M. Meyer

Erschienen in: CNS Drugs | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Several antipsychotics are associated with the ventricular tachycardia torsade de pointes (TdP), which may lead to sudden cardiac death (SCD), because of their inhibition of the cardiac delayed potassium rectifier channel. This inhibition extends the repolarization process of the ventricles of the heart, illustrated as a prolongation of the QT interval on a surface ECG. SCD in individuals receiving antipsychotics has an incidence of approximately 15 cases per 10 000 years of drug exposure but the exact association with TdP remains unknown because the diagnosis of TdP is uncertain. Most patients manifesting antipsychotic-associated TdP and subsequently SCD have well established risk factors for SCD, i.e. older age, female gender, hypokalaemia and cardiovascular disease.
QT interval prolongation is the most widely used surrogate marker for assessing the risk of TdP but it is considered somewhat imprecise, partly because QT interval changes are subject to measurement error. In particular, drug-induced T-wave changes (e.g. flattening of the T-wave) may complicate the measurement of the QT interval. Furthermore, the QT interval depends on the heart rate and a corrected QT (QTc) interval is often used to compensate for this. Several correction formulas have been suggested, with Bazett’s formula the most widely used. However, Bazett’s formula overcorrects at a heart rate above 80 beats per minute and, therefore, Fridericia’s formula is considered more appropriate to use in these cases. Several other surrogate markers for TdP have been developed but none of them is clinically implemented yet and QT interval prolongation is still considered the most valid surrogate marker. Although automated QT interval determination may offer some assistance, QT interval determination is best performed by a cardiologist skilled in its measurement.
A QT interval >500 ms markedly increases the risk for TdP and SCD, and should lead to discontinuation of the offending drug and, if present, correction of underlying electrolyte disturbances, particularly serum potassium and magnesium derangements. Before prescribing antipsychotics that may increase the QTc interval, the clinician should ask about family and personal history of SCD, presyncope, syncope and cardiac arrhythmias, and recommend cardiology consultation if history is positive.
Literatur
1.
Zurück zum Zitat Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss 1966 Feb; 59(2): 263–72PubMed Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss 1966 Feb; 59(2): 263–72PubMed
2.
Zurück zum Zitat Killeen MJ. Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry. Drug Discov Today 2009 Jun; 14(11–12): 589–97PubMed Killeen MJ. Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry. Drug Discov Today 2009 Jun; 14(11–12): 589–97PubMed
3.
Zurück zum Zitat Cohle SD, Sampson BA. The negative autopsy: sudden cardiac death or other? Cardiovasc Pathol 2001 Sep–Oct; 10(5): 219–22PubMed Cohle SD, Sampson BA. The negative autopsy: sudden cardiac death or other? Cardiovasc Pathol 2001 Sep–Oct; 10(5): 219–22PubMed
4.
Zurück zum Zitat Malik M. Drug-induced changes in the T-wave morphology. Drug Saf 2009; 32(7): 613–7PubMed Malik M. Drug-induced changes in the T-wave morphology. Drug Saf 2009; 32(7): 613–7PubMed
5.
Zurück zum Zitat Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is ‘normal’. J Cardiovasc Electrophysiol 2006 Mar; 17(3): 333–6PubMed Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is ‘normal’. J Cardiovasc Electrophysiol 2006 Mar; 17(3): 333–6PubMed
6.
Zurück zum Zitat Dogan A, Tunc E, Varol E, et al. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-aged healthy Turkish men. Ann Noninvasive Electrocardiol 2005 Apr; 10(2): 134–41PubMed Dogan A, Tunc E, Varol E, et al. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-aged healthy Turkish men. Ann Noninvasive Electrocardiol 2005 Apr; 10(2): 134–41PubMed
7.
Zurück zum Zitat Molnar J, Zhang F, Weiss J, et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996 Jan; 27(1): 76–83PubMed Molnar J, Zhang F, Weiss J, et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996 Jan; 27(1): 76–83PubMed
8.
Zurück zum Zitat Abdelmawla N, Mitchell A. Sudden cardiac death and antipsychotics, part 2: monitoring and prevention. Adv Psychiatr Treat 2006; 12: 100–9 Abdelmawla N, Mitchell A. Sudden cardiac death and antipsychotics, part 2: monitoring and prevention. Adv Psychiatr Treat 2006; 12: 100–9
9.
Zurück zum Zitat Nielsen J. The safety of atypical antipsychotics: does QTc provide all the answers? Expert Opin Drug Saf 2011 May; 10(3): 341–4PubMed Nielsen J. The safety of atypical antipsychotics: does QTc provide all the answers? Expert Opin Drug Saf 2011 May; 10(3): 341–4PubMed
10.
Zurück zum Zitat Drici MD, Priori S. Cardiovascular risks of atypical anti-psychotic drug treatment. Pharmacoepidemiol Drug Saf 2007 Aug; 16(8): 882–90PubMed Drici MD, Priori S. Cardiovascular risks of atypical anti-psychotic drug treatment. Pharmacoepidemiol Drug Saf 2007 Aug; 16(8): 882–90PubMed
11.
Zurück zum Zitat Hedley PL, Jorgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 2009 Nov; 30(11): 1486–511PubMed Hedley PL, Jorgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 2009 Nov; 30(11): 1486–511PubMed
12.
Zurück zum Zitat Quaglini S, Rognoni C, Spazzolini C, et al. Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J 2006 Aug; 27(15): 1824–32PubMed Quaglini S, Rognoni C, Spazzolini C, et al. Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J 2006 Aug; 27(15): 1824–32PubMed
13.
Zurück zum Zitat van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010 Jul; 70(1): 16–23PubMed van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010 Jul; 70(1): 16–23PubMed
14.
Zurück zum Zitat Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002 Apr 23; 105(16): 1943–8PubMed Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002 Apr 23; 105(16): 1943–8PubMed
15.
Zurück zum Zitat Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004 Mar; 82(3): 182–8PubMed Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004 Mar; 82(3): 182–8PubMed
16.
Zurück zum Zitat Lehtonen A, Fodstad H, Laitinen-Forsblom P, et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007 May; 4(5): 603–7PubMed Lehtonen A, Fodstad H, Laitinen-Forsblom P, et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007 May; 4(5): 603–7PubMed
17.
Zurück zum Zitat van Noord C, Aarnoudse AJ, Eijgelsheim M, et al. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenet Genomics 2009 Apr; 19(4): 260–6PubMed van Noord C, Aarnoudse AJ, Eijgelsheim M, et al. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenet Genomics 2009 Apr; 19(4): 260–6PubMed
18.
Zurück zum Zitat Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001 Nov; 158(11): 1774–82PubMed Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001 Nov; 158(11): 1774–82PubMed
19.
Zurück zum Zitat Killeen MJ, Sabir IN, Grace AA, et al. Dispersions of repolarization and ventricular arrhythmogenesis: lessons from animal models. Prog Biophys Mol Biol 2008 Oct–Nov; 98(2–3): 219–29PubMed Killeen MJ, Sabir IN, Grace AA, et al. Dispersions of repolarization and ventricular arrhythmogenesis: lessons from animal models. Prog Biophys Mol Biol 2008 Oct–Nov; 98(2–3): 219–29PubMed
20.
Zurück zum Zitat Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005 Sep; 20(5): 243–51PubMed Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005 Sep; 20(5): 243–51PubMed
21.
Zurück zum Zitat Salle P, Rey JL, Bernasconi P, et al. Torsades de pointe: apropos of 60 cases. Ann Cardiol Angeiol (Paris) 1985 Jun; 34(6): 381–8 Salle P, Rey JL, Bernasconi P, et al. Torsades de pointe: apropos of 60 cases. Ann Cardiol Angeiol (Paris) 1985 Jun; 34(6): 381–8
22.
Zurück zum Zitat Montanez A, Ruskin JN, Hebert PR, et al. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004 May 10; 164(9): 943–8PubMed Montanez A, Ruskin JN, Hebert PR, et al. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004 May 10; 164(9): 943–8PubMed
23.
Zurück zum Zitat Antonelli D, Atar S, Freedberg NA, et al. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J 2005 Mar; 7(3): 163–5PubMed Antonelli D, Atar S, Freedberg NA, et al. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J 2005 Mar; 7(3): 163–5PubMed
24.
Zurück zum Zitat Hondeghem LM. QT and TdP. QT: an unreliable predictor of proarrhythmia. Acta Cardiol 2008 Feb; 63(1): 1–7 Hondeghem LM. QT and TdP. QT: an unreliable predictor of proarrhythmia. Acta Cardiol 2008 Feb; 63(1): 1–7
25.
Zurück zum Zitat Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: apopulation-based cohort study (FIN 11 study). Lancet 2009 Aug 22; 374(9690): 620–7PubMed Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: apopulation-based cohort study (FIN 11 study). Lancet 2009 Aug 22; 374(9690): 620–7PubMed
26.
Zurück zum Zitat Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24(5): 323–51PubMed Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24(5): 323–51PubMed
27.
Zurück zum Zitat Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol 2007 Sep; 32(9): 501–46PubMed Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol 2007 Sep; 32(9): 501–46PubMed
28.
Zurück zum Zitat Rodriguez EM, Staffa JA, Graham DJ. The role of databasesin drug postmarketing surveillance. PharmacoepidemiolDrug Saf 2001 Aug–Sep; 10(5): 407–10 Rodriguez EM, Staffa JA, Graham DJ. The role of databasesin drug postmarketing surveillance. PharmacoepidemiolDrug Saf 2001 Aug–Sep; 10(5): 407–10
29.
Zurück zum Zitat Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24(8): 575–85PubMed Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24(8): 575–85PubMed
30.
Zurück zum Zitat Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010; 122(5): 345–55PubMed Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010; 122(5): 345–55PubMed
31.
Zurück zum Zitat Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991 May; 36(4): 239–45PubMed Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991 May; 36(4): 239–45PubMed
32.
Zurück zum Zitat Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009 Jan 15; 360(3): 225–35PubMed Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009 Jan 15; 360(3): 225–35PubMed
33.
Zurück zum Zitat Leucht S, Burkard T, Henderson J, et al. Physical illness nd schizophrenia: a review of the literature. Acta Psychiatr Scand 2007 Nov; 116(5): 317–33PubMed Leucht S, Burkard T, Henderson J, et al. Physical illness nd schizophrenia: a review of the literature. Acta Psychiatr Scand 2007 Nov; 116(5): 317–33PubMed
34.
Zurück zum Zitat Ritter JM. Drug-induced long QT syndrome and drug development. Br J Clin Pharmacol 2008 Sep; 66(3): 341–4PubMed Ritter JM. Drug-induced long QT syndrome and drug development. Br J Clin Pharmacol 2008 Sep; 66(3): 341–4PubMed
35.
Zurück zum Zitat Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997 Dec; 171: 502–8PubMed Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997 Dec; 171: 502–8PubMed
36.
Zurück zum Zitat Tong KL, Lau YS, Teo WS. A case series of drug-induced long QT syndrome and torsade de pointes. Singapore Med J 2001 Dec; 42(12): 566–70PubMed Tong KL, Lau YS, Teo WS. A case series of drug-induced long QT syndrome and torsade de pointes. Singapore Med J 2001 Dec; 42(12): 566–70PubMed
37.
Zurück zum Zitat Lindstrom E, Farde L, Eberhard J, et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005 Dec; 8(4): 615–29PubMed Lindstrom E, Farde L, Eberhard J, et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005 Dec; 8(4): 615–29PubMed
38.
Zurück zum Zitat Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003 Feb; 107(2): 85–95PubMed Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003 Feb; 107(2): 85–95PubMed
39.
Zurück zum Zitat Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003 Jul; 82(4): 282–90 Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003 Jul; 82(4): 282–90
40.
Zurück zum Zitat Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993 Mar 24–31; 269(12): 1532–6PubMed Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993 Mar 24–31; 269(12): 1532–6PubMed
41.
Zurück zum Zitat Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006 May; 46(5): 498–507PubMed Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006 May; 46(5): 498–507PubMed
42.
Zurück zum Zitat Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 2005; 28(1): 35–51PubMed Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 2005; 28(1): 35–51PubMed
43.
Zurück zum Zitat Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf 2010; 33(1): 1–14PubMed Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf 2010; 33(1): 1–14PubMed
44.
Zurück zum Zitat Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003 Apr 23–30; 289(16): 2120–7PubMed Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003 Apr 23–30; 289(16): 2120–7PubMed
45.
Zurück zum Zitat Widerlov E, Jostell KG, Claesson L, et al. Influence of food intake on electrocardiograms of healthy male volunteers. Eur J Clin Pharmacol 1999 Nov; 55(9): 619–24PubMed Widerlov E, Jostell KG, Claesson L, et al. Influence of food intake on electrocardiograms of healthy male volunteers. Eur J Clin Pharmacol 1999 Nov; 55(9): 619–24PubMed
46.
Zurück zum Zitat Malik M, Hnatkova K, Novotny T, et al. Subject-specific profiles of QT/RR hysteresis. Am J Physiol Heart Circ Physiol 2008 Dec; 295(6): H2356–63PubMed Malik M, Hnatkova K, Novotny T, et al. Subject-specific profiles of QT/RR hysteresis. Am J Physiol Heart Circ Physiol 2008 Dec; 295(6): H2356–63PubMed
47.
Zurück zum Zitat Sredniawa B, Musialik-Lydka A, Jarski P, et al. Methods of assessment and clinical relevance of QT dynamics. Indian Pacing Electrophysiol J 2005; 5(3): 221–32PubMed Sredniawa B, Musialik-Lydka A, Jarski P, et al. Methods of assessment and clinical relevance of QT dynamics. Indian Pacing Electrophysiol J 2005; 5(3): 221–32PubMed
48.
Zurück zum Zitat Malik M. Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. J Electrocardiol 2004; 37 Suppl. : 25–33PubMed Malik M. Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. J Electrocardiol 2004; 37 Suppl. : 25–33PubMed
49.
Zurück zum Zitat Malik M, Hnatkova K, Schmidt A, et al. Correction for QT/RR hysteresis in the assessment of drug-induced QTc changes: cardiac safety of gadobutrol. Ann Noninvasive Electrocardiol 2009 Jul; 14(3): 242–50PubMed Malik M, Hnatkova K, Schmidt A, et al. Correction for QT/RR hysteresis in the assessment of drug-induced QTc changes: cardiac safety of gadobutrol. Ann Noninvasive Electrocardiol 2009 Jul; 14(3): 242–50PubMed
50.
Zurück zum Zitat Jensen BT, Larroude CE, Rasmussen LP, et al. Beat-to-beat QT dynamics in healthy subjects. Ann Noninvasive Electrocardiol 2004 Jan; 9(1): 3–11PubMed Jensen BT, Larroude CE, Rasmussen LP, et al. Beat-to-beat QT dynamics in healthy subjects. Ann Noninvasive Electrocardiol 2004 Jan; 9(1): 3–11PubMed
51.
Zurück zum Zitat Smetana P, Batchvarov V, Hnatkova K, et al. Circadian rhythm of the corrected QT interval: impact of different heart rate correction models. Pacing Clin Electrophysiol 2003 Jan; 26(1 Pt 2): 383–6PubMed Smetana P, Batchvarov V, Hnatkova K, et al. Circadian rhythm of the corrected QT interval: impact of different heart rate correction models. Pacing Clin Electrophysiol 2003 Jan; 26(1 Pt 2): 383–6PubMed
52.
Zurück zum Zitat Graff C, Andersen MP, Xue JQ, et al. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Drug Saf 2009; 32(7): 599–611PubMed Graff C, Andersen MP, Xue JQ, et al. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Drug Saf 2009; 32(7): 599–611PubMed
53.
Zurück zum Zitat Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60: 681–90PubMed Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60: 681–90PubMed
54.
Zurück zum Zitat Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003 Jun 1; 61: 123–36PubMed Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003 Jun 1; 61: 123–36PubMed
55.
Zurück zum Zitat Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of oralziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy 2010 Feb; 30(2): 127–35PubMed Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of oralziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy 2010 Feb; 30(2): 127–35PubMed
56.
Zurück zum Zitat Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004 Feb; 24(1): 62–9PubMed Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004 Feb; 24(1): 62–9PubMed
57.
Zurück zum Zitat Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 Oct; 17: 407–18PubMed Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 Oct; 17: 407–18PubMed
58.
Zurück zum Zitat Desta Z, Kerbusch T, Flockhart DA. Effect of clarithro-mycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999 Jan; 65: 10–20PubMed Desta Z, Kerbusch T, Flockhart DA. Effect of clarithro-mycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999 Jan; 65: 10–20PubMed
59.
Zurück zum Zitat Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010 May; 121(5): 385–8PubMed Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010 May; 121(5): 385–8PubMed
60.
Zurück zum Zitat Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996 Nov;60: 543–53PubMed Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996 Nov;60: 543–53PubMed
61.
Zurück zum Zitat Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009; 19(10): 702–7PubMed Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009; 19(10): 702–7PubMed
62.
Zurück zum Zitat Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003; 17(6): 423–30PubMed Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003; 17(6): 423–30PubMed
63.
Zurück zum Zitat Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002; 63 Suppl. 9: 12–7 Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002; 63 Suppl. 9: 12–7
64.
Zurück zum Zitat Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005 Jan 25; 4(1): 1PubMed Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005 Jan 25; 4(1): 1PubMed
65.
Zurück zum Zitat Michelsen JW, Meyer JM. Cardiovascular effects of anti-psychotics. Expert Rev Neurother 2007 Jul; 7(7): 829–39PubMed Michelsen JW, Meyer JM. Cardiovascular effects of anti-psychotics. Expert Rev Neurother 2007 Jul; 7(7): 829–39PubMed
66.
Zurück zum Zitat Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993 Aug 26; 72(6): 23B-5B Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993 Aug 26; 72(6): 23B-5B
67.
Zurück zum Zitat Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 Mar 4; 350(10): 1013–22PubMed Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 Mar 4; 350(10): 1013–22PubMed
68.
Zurück zum Zitat Bazett HC. An analysis of the time relationship of electrocardiograms. Heart 1920; 7: 353–70 Bazett HC. An analysis of the time relationship of electrocardiograms. Heart 1920; 7: 353–70
69.
Zurück zum Zitat Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen menschen und bei herzkranken [letter]. Acta Med Scand 1920; 53: 489 Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen menschen und bei herzkranken [letter]. Acta Med Scand 1920; 53: 489
70.
Zurück zum Zitat Darpo B, Agin M, Kazierad DJ, et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 2006 Jun; 46(6): 598–612PubMed Darpo B, Agin M, Kazierad DJ, et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 2006 Jun; 46(6): 598–612PubMed
71.
Zurück zum Zitat Kanters JK, Fanoe S, Larsen LA, et al. T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in long QT syndrome. Heart Rhythm 2004 Sep; 1(3): 285–92PubMed Kanters JK, Fanoe S, Larsen LA, et al. T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in long QT syndrome. Heart Rhythm 2004 Sep; 1(3): 285–92PubMed
72.
Zurück zum Zitat Savelieva I, Yi G, Guo X, et al. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol 1998 Feb 15; 81(4): 471–7PubMed Savelieva I, Yi G, Guo X, et al. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol 1998 Feb 15; 81(4): 471–7PubMed
73.
Zurück zum Zitat Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952 Sep; 6(3): 378–88PubMed Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952 Sep; 6(3): 378–88PubMed
74.
Zurück zum Zitat Tisdale JE, Rasty S, Padhi ID, et al. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001 Dec; 41(12): 1310–8PubMed Tisdale JE, Rasty S, Padhi ID, et al. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001 Dec; 41(12): 1310–8PubMed
75.
Zurück zum Zitat Kors JA, van Herpen G. Measurement error as a source of QT dispersion: a computerised analysis. Heart 1998 Nov; 80(5): 453–8PubMed Kors JA, van Herpen G. Measurement error as a source of QT dispersion: a computerised analysis. Heart 1998 Nov; 80(5): 453–8PubMed
76.
Zurück zum Zitat Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998 Nov 3; 98(18): 1928–36PubMed Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998 Nov 3; 98(18): 1928–36PubMed
77.
Zurück zum Zitat Kanters JK, Haarmark C, Vedel-Larsen E, et al. T(peak)- T(end) interval in long QT syndrome. J Electrocardiol 2008 Nov–Dec; 41(6): 603–8PubMed Kanters JK, Haarmark C, Vedel-Larsen E, et al. T(peak)- T(end) interval in long QT syndrome. J Electrocardiol 2008 Nov–Dec; 41(6): 603–8PubMed
78.
Zurück zum Zitat Graff C, Struijk JJ, Matz J, et al. Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization. Clin Pharmacol Ther 2010 Jul; 88(1): 88–94PubMed Graff C, Struijk JJ, Matz J, et al. Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization. Clin Pharmacol Ther 2010 Jul; 88(1): 88–94PubMed
79.
Zurück zum Zitat Struijk JJ, Kanters JK, Andersen MP, et al. Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput 2006 Jul; 44(7): 543–9PubMed Struijk JJ, Kanters JK, Andersen MP, et al. Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput 2006 Jul; 44(7): 543–9PubMed
80.
Zurück zum Zitat Andersen MP, Xue JQ, Graff C, et al. New descriptors of T-wave morphology are independent of heart rate. J Electrocardiol 2008 Nov–Dec; 41(6): 557–61PubMed Andersen MP, Xue JQ, Graff C, et al. New descriptors of T-wave morphology are independent of heart rate. J Electrocardiol 2008 Nov–Dec; 41(6): 557–61PubMed
81.
Zurück zum Zitat Graff C, Matz J, Christensen EB, et al. Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35–138. J Clin Pharmacol 2009 Nov; 49(11): 1331–42PubMed Graff C, Matz J, Christensen EB, et al. Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35–138. J Clin Pharmacol 2009 Nov; 49(11): 1331–42PubMed
82.
Zurück zum Zitat Kanters JK, Graff C, Andersen MP, et al. Long QT syndrome genotyping by electrocardiography: fact, fiction, or something in between? J Electrocardiol 2006 Oct; 39(4 Suppl. ): S1 19–22 Kanters JK, Graff C, Andersen MP, et al. Long QT syndrome genotyping by electrocardiography: fact, fiction, or something in between? J Electrocardiol 2006 Oct; 39(4 Suppl. ): S1 19–22
83.
Zurück zum Zitat Axelsson R, Aspenstrom G. Electrocardiographic changes and serum concentrations in thioridazine-treated patients. J Clin Psychiatry 1982 Aug; 43(8): 332–5PubMed Axelsson R, Aspenstrom G. Electrocardiographic changes and serum concentrations in thioridazine-treated patients. J Clin Psychiatry 1982 Aug; 43(8): 332–5PubMed
84.
Zurück zum Zitat Alvarez-Mena SC, Frank MJ. Phenothiazine-induced T-wave abnormalities: effects of overnight fasting. JAMA 1973 Jun 25; 224(13): 1730–3PubMed Alvarez-Mena SC, Frank MJ. Phenothiazine-induced T-wave abnormalities: effects of overnight fasting. JAMA 1973 Jun 25; 224(13): 1730–3PubMed
85.
Zurück zum Zitat Correll CU, Nielsen J. Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand 2010 Nov; 122(5): 341–4PubMed Correll CU, Nielsen J. Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand 2010 Nov; 122(5): 341–4PubMed
86.
Zurück zum Zitat Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia: the Sertindole Study Group. Psychopharmacol Bull 1998; 34(1): 61–9PubMed Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia: the Sertindole Study Group. Psychopharmacol Bull 1998; 34(1): 61–9PubMed
87.
Zurück zum Zitat Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010 Feb; 71(2): 103–8PubMed Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010 Feb; 71(2): 103–8PubMed
88.
Zurück zum Zitat Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998 Oct; 173: 325–9PubMed Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998 Oct; 173: 325–9PubMed
89.
Zurück zum Zitat Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008 Jun; 192(6): 435–9 Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008 Jun; 192(6): 435–9
90.
Zurück zum Zitat Nielsen J, le Quach P, Emborg C, et al. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010 Nov; 122(5): 356–66PubMed Nielsen J, le Quach P, Emborg C, et al. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010 Nov; 122(5): 356–66PubMed
91.
Zurück zum Zitat Lancon C, Toumi M, Sapin C, et al. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 2008; 8: 57PubMed Lancon C, Toumi M, Sapin C, et al. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 2008; 8: 57PubMed
92.
Zurück zum Zitat Kasper S, Moller HJ, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010 Feb; 260(1): 59–68PubMed Kasper S, Moller HJ, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010 Feb; 260(1): 59–68PubMed
93.
Zurück zum Zitat Peuskens J, Moore N, Azorin JM, et al. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007 Jul; 16(7): 804–11PubMed Peuskens J, Moore N, Azorin JM, et al. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007 Jul; 16(7): 804–11PubMed
94.
Zurück zum Zitat Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011 Feb; 168(2): 193–201PubMed Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011 Feb; 168(2): 193–201PubMed
95.
Zurück zum Zitat Nielsen J, Dahm M, Lublin H, et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010 Jul; 24(7): 965–71PubMed Nielsen J, Dahm M, Lublin H, et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010 Jul; 24(7): 965–71PubMed
96.
Zurück zum Zitat Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002; 21(4): 189–203PubMed Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002; 21(4): 189–203PubMed
97.
Zurück zum Zitat Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009 Feb 16; 190(4): 190–2PubMed Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009 Feb 16; 190(4): 190–2PubMed
98.
Zurück zum Zitat ADA. Consensus development conference on anti-psychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601 ADA. Consensus development conference on anti-psychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601
99.
Zurück zum Zitat Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death: how should we manage the risk? N Engl J Med 2009 Jan 15; 360(3): 294–6PubMed Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death: how should we manage the risk? N Engl J Med 2009 Jan 15; 360(3): 294–6PubMed
100.
Zurück zum Zitat Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in anti-psychotic-naive schizophrenia patients. Neuropsycho-pharmacology 2010 Aug; 35(9): 1997–200 Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in anti-psychotic-naive schizophrenia patients. Neuropsycho-pharmacology 2010 Aug; 35(9): 1997–200
101.
Zurück zum Zitat Munk-Jørgensen P, Nielsen J, Nielsen RE, et al. Last episode psychosis. Acta Psychiatr Scand 2009 Jun; 119(6): 417–8PubMed Munk-Jørgensen P, Nielsen J, Nielsen RE, et al. Last episode psychosis. Acta Psychiatr Scand 2009 Jun; 119(6): 417–8PubMed
102.
Zurück zum Zitat Meltzer HY, Davidson M, Glassman AH, et al. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002; 63 Suppl. 9: 25–9 Meltzer HY, Davidson M, Glassman AH, et al. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002; 63 Suppl. 9: 25–9
Metadaten
Titel
Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics
verfasst von
Dr Jimmi Nielsen
Claus Graff
Jørgen K. Kanters
Egon Toft
David Taylor
Jonathan M. Meyer
Publikationsdatum
01.06.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11587800-000000000-00000

Weitere Artikel der Ausgabe 6/2011

CNS Drugs 6/2011 Zur Ausgabe

Adis Drug Evaluation

Oral Paliperidone

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.